From A(erie) To Z(ynerba): Biotech Catalysts Lined Up For Second Half Of 2017


Between late-stage readouts and regulatory events, the biotech industry has enough second-half catalysts to potentially actualize Cantor Fitzgerald's investment theses and justify its price targets, according to the firm's recent note. The most imminent is Versartis Inc 's September release of phase 3 data from its somavaratan study , which compares the drug against Pfizer Inc. 's Genotropin in patients with pediatric hormone growth deficiency.



from Biotech News